|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficiency of Double Layered Microencapsulated Probiotic to Modulate ProInflammatory Molecular Markers for the Management of Alcoholic Liver Disease显示文摘 | Sumeha Arora Indu Pal Kaur Kanwaljit Chopra Praveen Rishi José Cesar Rosa | 2014 | Mediators of Inflammation2014，，： | 2 |
| 2 | Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative–nitrosative stress in rats显示文摘 | Vinod Tiwari Anurag Kuhad Mahendra Bishnoi Kanwaljit Chopra | 2009 | Pharmacology, Biochemistry and Behavior2009，，2： | 2 |
| 3 | Catechin suppresses an array of signalling molecules and modulates alcohol - induced en- dotoxin mediated liver injury in a rat model 显示文摘 | Sushma B Ashwani K Kanwaljit C | 2011 | PLoS ONE2011，6，6： | 1 |
| 4 | Evaluating a web-based self-management program for employees with hypertension and prehypertension: A randomized clinical trial显示文摘 | Alice J. Watson Kanwaljit Singh Khinlei Myint-U Richard W. Grant Kamal Jethwani Ellen Murachver Kimberly Harris Thomas H. Lee Joseph C. Kvedar | 2012 | American Heart Journal2012，，4： | 1 |
| 5 | Pathobiological targets of depression显示文摘 | Kanwaljit Chopra Baldeep Kumar Anurag Kuhad | 2011 | Expert Opinion on Therapeutic Targets2011，，4： | 1 |
| 6 | Probiotics:potential pharmaceutical application显示文摘 | INDU P K KANWALJIT C AMARPREET S | 2002 | European Journal of Pharmaceutical Sciences2002，15，1： | 1 |
| 7 | Protective Effect of L-type Calcium Channel Blockers Against Haloperidol-induced Orofacial Dyskinesia:A Behavioural,Biochemical and Neurochemical Study显示文摘 | Mahendra B Kanwaljit C Shrinivas KK | | 0，，： | 1 |
| 8 | Delineation of antimutagenic activity of catechin,epicatechinand green tea extract显示文摘 | Thiraviam G Amita G Kanwaljit C | 2004 | Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis2004，556，12： | 1 |
| 9 | EPR and thermal studies on the reaction of copper acetate with 8 -hydrox- yquinoline in the solid phase 显示文摘 | Bassi P S Chopra G S Kanwaljit kaur | 1990 | Indian Journal of Chemistry1990，29，5： | 1 |
| 10 | Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model显示文摘 | Amit Gupta Garima Vij Sameer Sharma Naveen Tirkey Praveen Rishi Kanwaljit Chopra | 2008 | Immunobiology2008，，1： | 1 |
| 11 | Probiotics: Potential Pharmaceutical Applications 显示文摘 | Indu Pal Kaur Kanwaljit Chopra and Amarpreet Saini | 2002 | European Journal of Pharmaceutical Sciences2002，15，1： | 1 |
| 12 | EPR and thermal studies on the reaction of copper acetate with 8 - hydroxyquinoline in the solid phase显示文摘 | Bassi P S Chopra G S Kanwaljit kaur | 1990 | Indian Journal of Chemistry1990，29，5： | 1 |
| 13 | Possible role of oxidative stress and immunological activation in mouse model of chronic fatigue syndrome and its attenuation by olive extract显示文摘 | Amit Gupta Garima Vij Kanwaljit Chopra | 2010 | Journal of Neuroimmunology2010，，1： | 1 |
| 14 | EPR and thermal studies on the reaction of copper acetate with 8-hydroxyquinoline in the solid phase显示文摘 | Bassi P S Chopra G S Kanwaljit Kaur | 1990 | Indian Journal of Chemistry1990，29，5： | 1 |
| 15 | Beneficial effect of hesperidin on lipopolysaccharide-indueed Hepatotoxicity 显示文摘 | Gaganjit K Naveen T Kanwaljit C | 2006 | Toxicology2006，226，23： | 1 |
| 16 | Tocotrienol attenuates oxidative–nitrosative stress and inflammatory cascade in experimental model of diabetic neuropathy显示文摘 | Anurag Kuhad Kanwaljit Chopra | 2009 | Neuropharmacology2009，，4： | 1 |
| 17 | Pathobiological targets of depression显示文摘 | Kanwaljit Chopra Baldeep Kumar Anurag Kuhad | 2011 | Expert Opinion on Therapeutic Targets2011，，4： | 1 |
| 18 | Pathobiological targets of depression显示文摘 | Kanwaljit Chopra Baldeep Kumar Anurag Kuhad | 2011 | Expert Opinion on Therapeutic Targets2011，，4： | 1 |
| 19 | Antibody induction therapy in adult kidney transplantation: A controversy continues显示文摘Antibody induction therapy is frequently used as an adjunct to the maintenance immunosuppression in adult kidney transplant recipients. Published data support antibody induction in patients with immunologic risk to reduce the incidence of acute rejection(AR) and graft loss from rejection. However, the choice of antibody remains controversial as the clinical studies were carried out on patients of different immunologic risk and in the context of varying maintenance regimens. Antibody selection should be guided by a comprehensive assessment of immunologic risk, patient comorbidities, financial burden as well as the maintenance immunosuppressives. Lymphocyte-depleting antibody(thymoglobulin, ATGAM or alemtuzumab) is usually recommended for those with high risk of rejection, although it increases the risk of infection and malignancy. For low risk patients, interleukin-2 receptor antibody(basiliximab or daclizumab) reduces the incidence of AR without much adverse effects, making its balance favorable in mostpatients. It should also be used in the high risk patients with other medical comorbidities that preclude usage of lymphocyte-depleting antibody safely. There are many patients with very low risk, who may be induced with intravenous steroids without any antibody, as long as combined potent immunosuppressives are kept as maintenance. In these patients, benefits with antibody induction may be too small to outweigh its adverse effects and financial cost. Rituximab can be used in desensitization protocols for ABO and/or HLA incompatible transplants. There are emerging data suggesting that alemtuzumab induction be more successful than other antibody for promoting less intensive maintenance protocols, such as steroid withdrawal, tacrolimus monotherapy or lower doses of tacrolimus and mycophenolic acid. However, the long-term efficacy and safety of these unconventional strategies remains unknown. | Kanwaljit K Chouhan Rubin Zhang | 2012 | World Journal of Transplantation2012，2，2： | 1 |
| 20 | Current perspectives on pharmaco- therapy of Alzheimers disease 显示文摘 | Kanwaljit C Shubham M Anurag K | 2011 | Expert Opinion Pharmacother2011，12，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员